COMP <GO>
DNTH vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Dianthus Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DNTH 2
— UNH 10
■ METRIC PARITY
LAST: $82.70 (+0.47%) • MKT CAP: $4.63B
options-implied-move
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNTH VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DNTH | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.70% | 11.47% | -42.17 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.79% | 6.48% | -9.27 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.46% | -71.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 59.2 | -11.60 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | DNTH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 17.1x | +2.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.63B | $368.83B | -$364.20B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DNTH REV | UNH REV | DNTH GROSS % | UNH GROSS % | DNTH FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $447.57B | — | 88.7% | -$129.2M | $16.07B |
| FY 2024 | $6.2M | $400.28B | — | 88.3% | -$78.5M | $20.70B |
| FY 2023 | $2.8M | $371.62B | — | 89.6% | -$37.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNTH // BETA 1.08
UNH // BETA 0.33